Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Jenny C. Chang, MD
- Registration Number
- NCT02725541
- Locations
- ๐บ๐ธ
Houston Methodist Hospital, Houston, Texas, United States
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Jenny C. Chang, MD
- Target Recruit Count
- 24
- Registration Number
- NCT02073916
- Locations
- ๐บ๐ธ
Houston Methodist Hospital, Houston, Texas, United States
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
Phase 2
Withdrawn
- Conditions
- Breast Cancer
- Interventions
- Drug: taxane-based chemotherapyDrug: Anthracycline based chemotherapy
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Jenny C. Chang, MD
- Registration Number
- NCT02067416
- Locations
- ๐บ๐ธ
Houston Methodist Hospital, Houston, Texas, United States
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Jenny C. Chang, MD
- Target Recruit Count
- 24
- Registration Number
- NCT01931163
- Locations
- ๐บ๐ธ
The Methodist Hospital, Houston, Texas, United States
๐บ๐ธHouston Methodist Hospital Willowbrook, Houston, Texas, United States
๐บ๐ธHouston Methodist Hospital Sugar Land, Sugar Land, Texas, United States